What's in Tibotec Pharmaceuticals, Ireland's pipeline?

Tibotec Pharmaceuticals, Ireland has 19 drugs in our index: 2 marketed, 0 filed, 6 in Phase 3, 2 in Phase 2, 9 in Phase 1.

Which companies overlap with Tibotec Pharmaceuticals, Ireland's portfolio?

Top competitors by shared drug class: French National Agency for Research on AIDS and Viral Hepatitis, Merck Sharp & Dohme LLC, ViiV Healthcare, Hoffmann-La Roche, Germans Trias i Pujol Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/tibotec-pharmaceuticals-ireland.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Tibotec Pharmaceuticals, Ireland — Portfolio Competitive Intelligence Brief

Tibotec Pharmaceuticals, Ireland pipeline: 2 marketed, 0 filed, 6 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 6 Phase 3 2 Phase 2 9 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Ribavirin (R)	Ribavirin (R)	marketed	Nucleoside analog antiviral	Viral RNA-dependent RNA polymerase; guanosine triphosphate metabolism	Virology/Infectious Disease
TMC278	TMC278	marketed			Other
TMC-114/RTV	TMC-114/RTV	phase 3	Protease inhibitor	HIV protease	Infectious diseases
TMC114	TMC114	phase 3	protease inhibitor	HIV-1 protease	Infectious Diseases
TMC114/rtv	TMC114/rtv	phase 3	protease inhibitor	HIV protease	Infectious disease
TMC435	TMC435	phase 3	protease inhibitor	HIV-1 protease	Infectious Diseases
Darunavir (DRV)	Darunavir (DRV)	phase 3	HIV protease inhibitor	HIV protease	Infectious Disease
TMC125	TMC125	phase 3	Non-nucleoside reverse transcriptase inhibitor (NNRTI)	Reverse transcriptase	Infectious Disease

Therapeutic area mix

Infectious Disease · 2
Infectious Diseases · 2
Other · 2
Infectious disease · 1
Infectious diseases · 1
Virology/Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

French National Agency for Research on AIDS and Viral Hepatitis · 4 shared drug classes
Merck Sharp & Dohme LLC · 3 shared drug classes
ViiV Healthcare · 3 shared drug classes
Hoffmann-La Roche · 2 shared drug classes
Germans Trias i Pujol Hospital · 2 shared drug classes
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 2 shared drug classes
Göteborg University · 2 shared drug classes
Ain Shams University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Tibotec Pharmaceuticals, Ireland:

Cite this brief

Drug Landscape (2026). Tibotec Pharmaceuticals, Ireland — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/tibotec-pharmaceuticals-ireland. Accessed 2026-05-16.